Research ExplorerPublicationsRisk factors for mixed chimerism in children with hemophagoc...

Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning

Standard

Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. / Wustrau, Katharina; Greil, Johann; Sykora, Karl-Walter; Albert, Michael H; Burkhardt, Birgit; Lang, Peter; Meisel, Roland; Wössmann, Wilhelm; Beier, Rita; Schulz, Ansgar; Bader, Peter; Chada, Martin; Kühl, Jörn-Sven; Schlegel, Paul-Gerhardt; Speckmann, Carsten; Gruhn, Bernd; Seidel, Markus; Wawer, Angela; Ozga, Ann-Kathrin; Janka, Gritta; Ehl, Stephan; Müller, Ingo; Lehmberg, Kai.

In: PEDIATR BLOOD CANCER, Vol. 67, No. 9, 09.2020, p. e28523.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wustrau, K, Greil, J, Sykora, K-W, Albert, MH, Burkhardt, B, Lang, P, Meisel, R, Wössmann, W, Beier, R, Schulz, A, Bader, P, Chada, M, Kühl, J-S, Schlegel, P-G, Speckmann, C, Gruhn, B, Seidel, M, Wawer, A, Ozga, A-K, Janka, G, Ehl, S, Müller, I & Lehmberg, K 2020, 'Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning', PEDIATR BLOOD CANCER, vol. 67, no. 9, pp. e28523. https://doi.org/10.1002/pbc.28523

APA

Wustrau, K., Greil, J., Sykora, K-W., Albert, M. H., Burkhardt, B., Lang, P., Meisel, R., Wössmann, W., Beier, R., Schulz, A., Bader, P., Chada, M., Kühl, J-S., Schlegel, P-G., Speckmann, C., Gruhn, B., Seidel, M., Wawer, A., Ozga, A-K., ... Lehmberg, K. (2020). Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. PEDIATR BLOOD CANCER, 67(9), e28523. https://doi.org/10.1002/pbc.28523

Vancouver

Wustrau K, Greil J, Sykora K-W, Albert MH, Burkhardt B, Lang P et al. Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. PEDIATR BLOOD CANCER. 2020 Sep;67(9):e28523. https://doi.org/10.1002/pbc.28523

Bibtex

@article{d8c82fca1c524237b6ef10dabf6087ef,
title = "Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning",
abstract = "BACKGROUND: Reduced toxicity conditioning for hematopoietic stem cell transplantation of patients with hemophagocyticlymphohistiocytosis (HLH) results in favorable survival, however at the expense of relevant rates of mixed chimerism. Factors predisposing to mixed chimerism remain to be determined.PROCEDURE: Patients with primary HLH transplanted 2009-2016 after treosulfan- or melphalan-based conditioning regimens were analyzed in a retrospective multicenter study for survival, engraftment, chimerism, and adverse events. Mixed chimerism was considered substantial if < 25% donor chimerism occurred and/or if secondary cell therapy was administered. Donor type, graft source, type of alkylating agent, type of serotherapy, and remission status were analyzed as potential risk factors in a multivariable logistic regression model.RESULTS: Among 60 patients, engraftment was achieved in 95%, and the five-year estimated overall survival rate was 75%. Prevalence of any recipient chimerism was 48%. Substantial recipient chimerism was recorded in 32% of patients. Secondary post-HSCT cell therapy was administered in 30% of patients. A human leukocyte antigen (HLA)-mismatched donor (< 10/10) was the only significant risk factor for the occurrence of substantial recipient chimerism (P = 0.01; odds ratio, 5.8; CI 95%, 1.5-26.3).CONCLUSION: The use of an HLA-matched donor is the most important factor to avoid substantial recipient chimerism following treosulfan -or melphalan-based conditioning in primary HLH.",
author = "Katharina Wustrau and Johann Greil and Karl-Walter Sykora and Albert, {Michael H} and Birgit Burkhardt and Peter Lang and Roland Meisel and Wilhelm W{\"o}ssmann and Rita Beier and Ansgar Schulz and Peter Bader and Martin Chada and J{\"o}rn-Sven K{\"u}hl and Paul-Gerhardt Schlegel and Carsten Speckmann and Bernd Gruhn and Markus Seidel and Angela Wawer and Ann-Kathrin Ozga and Gritta Janka and Stephan Ehl and Ingo M{\"u}ller and Kai Lehmberg",
note = "{\textcopyright} 2020 Wiley Periodicals LLC.",
year = "2020",
month = sep,
doi = "10.1002/pbc.28523",
language = "English",
volume = "67",
pages = "e28523",
journal = "PEDIATR BLOOD CANCER",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning

AU - Wustrau, Katharina

AU - Greil, Johann

AU - Sykora, Karl-Walter

AU - Albert, Michael H

AU - Burkhardt, Birgit

AU - Lang, Peter

AU - Meisel, Roland

AU - Wössmann, Wilhelm

AU - Beier, Rita

AU - Schulz, Ansgar

AU - Bader, Peter

AU - Chada, Martin

AU - Kühl, Jörn-Sven

AU - Schlegel, Paul-Gerhardt

AU - Speckmann, Carsten

AU - Gruhn, Bernd

AU - Seidel, Markus

AU - Wawer, Angela

AU - Ozga, Ann-Kathrin

AU - Janka, Gritta

AU - Ehl, Stephan

AU - Müller, Ingo

AU - Lehmberg, Kai

N1 - © 2020 Wiley Periodicals LLC.

PY - 2020/9

Y1 - 2020/9

N2 - BACKGROUND: Reduced toxicity conditioning for hematopoietic stem cell transplantation of patients with hemophagocyticlymphohistiocytosis (HLH) results in favorable survival, however at the expense of relevant rates of mixed chimerism. Factors predisposing to mixed chimerism remain to be determined.PROCEDURE: Patients with primary HLH transplanted 2009-2016 after treosulfan- or melphalan-based conditioning regimens were analyzed in a retrospective multicenter study for survival, engraftment, chimerism, and adverse events. Mixed chimerism was considered substantial if < 25% donor chimerism occurred and/or if secondary cell therapy was administered. Donor type, graft source, type of alkylating agent, type of serotherapy, and remission status were analyzed as potential risk factors in a multivariable logistic regression model.RESULTS: Among 60 patients, engraftment was achieved in 95%, and the five-year estimated overall survival rate was 75%. Prevalence of any recipient chimerism was 48%. Substantial recipient chimerism was recorded in 32% of patients. Secondary post-HSCT cell therapy was administered in 30% of patients. A human leukocyte antigen (HLA)-mismatched donor (< 10/10) was the only significant risk factor for the occurrence of substantial recipient chimerism (P = 0.01; odds ratio, 5.8; CI 95%, 1.5-26.3).CONCLUSION: The use of an HLA-matched donor is the most important factor to avoid substantial recipient chimerism following treosulfan -or melphalan-based conditioning in primary HLH.

AB - BACKGROUND: Reduced toxicity conditioning for hematopoietic stem cell transplantation of patients with hemophagocyticlymphohistiocytosis (HLH) results in favorable survival, however at the expense of relevant rates of mixed chimerism. Factors predisposing to mixed chimerism remain to be determined.PROCEDURE: Patients with primary HLH transplanted 2009-2016 after treosulfan- or melphalan-based conditioning regimens were analyzed in a retrospective multicenter study for survival, engraftment, chimerism, and adverse events. Mixed chimerism was considered substantial if < 25% donor chimerism occurred and/or if secondary cell therapy was administered. Donor type, graft source, type of alkylating agent, type of serotherapy, and remission status were analyzed as potential risk factors in a multivariable logistic regression model.RESULTS: Among 60 patients, engraftment was achieved in 95%, and the five-year estimated overall survival rate was 75%. Prevalence of any recipient chimerism was 48%. Substantial recipient chimerism was recorded in 32% of patients. Secondary post-HSCT cell therapy was administered in 30% of patients. A human leukocyte antigen (HLA)-mismatched donor (< 10/10) was the only significant risk factor for the occurrence of substantial recipient chimerism (P = 0.01; odds ratio, 5.8; CI 95%, 1.5-26.3).CONCLUSION: The use of an HLA-matched donor is the most important factor to avoid substantial recipient chimerism following treosulfan -or melphalan-based conditioning in primary HLH.

U2 - 10.1002/pbc.28523

DO - 10.1002/pbc.28523

M3 - SCORING: Journal article

C2 - 32618429

VL - 67

SP - e28523

JO - PEDIATR BLOOD CANCER

JF - PEDIATR BLOOD CANCER

SN - 1545-5009

IS - 9

ER -